Oramed Pharmaceuticals to Acquire N.R. Labs Ltd.
Ticker: ORMP · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.012, $20,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, pipeline-expansion, merger
TL;DR
Oramed is buying N.R. Labs to boost its drug pipeline, deal expected to close Q3 2024.
AI Summary
Oramed Pharmaceuticals Inc. announced on June 26, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of the privately held company, N.R. Labs Ltd. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. This strategic move aims to expand Oramed's pipeline and therapeutic offerings.
Why It Matters
This acquisition could significantly expand Oramed's drug development pipeline, potentially leading to new treatments and increased market presence.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility that the acquired company's assets may not perform as expected.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- N.R. Labs Ltd. (company) — Target company for acquisition
- June 26, 2024 (date) — Date of the agreement and report
- Third quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on Oramed Pharmaceuticals Inc.'s entry into a definitive agreement to acquire N.R. Labs Ltd.
What is the name of the company Oramed Pharmaceuticals Inc. is acquiring?
Oramed Pharmaceuticals Inc. is acquiring N.R. Labs Ltd.
When is the acquisition of N.R. Labs Ltd. expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions.
What is the strategic rationale behind this acquisition for Oramed Pharmaceuticals Inc.?
The acquisition is intended to expand Oramed's pipeline and therapeutic offerings.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-06-26 09:00:10
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel
- $20,000,000 — may, from time to time, purchase up to $20,000,000 in maximum value of its common stock. S
Filing Documents
- ea0208443-8k_oramed.htm (8-K) — 22KB
- 0001213900-24-055950.txt ( ) — 190KB
- ormp-20240625.xsd (EX-101.SCH) — 3KB
- ormp-20240625_lab.xml (EX-101.LAB) — 33KB
- ormp-20240625_pre.xml (EX-101.PRE) — 22KB
- ea0208443-8k_oramed_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On June 26, 2024, Oramed Pharmaceuticals Inc. (the "Company") announced that the Company's Board of Directors authorized a stock buyback program (the "Stock Buy Back Program"), pursuant to which the Company may, from time to time, purchase up to $20,000,000 in maximum value of its common stock. Share repurchases may be executed through various means, including, without limitation, open market transactions, privately negotiated transactions or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934. The Stock Buy Back Program does not obligate the Company to purchase any shares and expires in 12 months. The authorization for the Stock Buy Back Program may be terminated, increased or decreased by the Company's Board of Directors in its discretion at any time. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO June 26, 2024 2